Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3911-3920

  Qu, Chun Ying ^a   Zhou, Min ^a   Chen, Ying Wei ^b   Chen, Mei Mei ^a   Shen, Feng ^a   Xu, Lei Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition   (China)

Author keywords

Combination chemotherapy; Gastric cancer; Hyaluronic acid; Lipid prodrug; Nanostructured lipid carriers

Indexed keywords

CISPLATIN; FLUOROURACIL; HYALURONIC ACID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOCOMPATIBLE COATED MATERIAL; LIPID; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION EFFICIENCY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; STOMACH CANCER; STRUCTURE ANALYSIS; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG RELEASE; NUDE MOUSE; STOMACH NEOPLASMS; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COATED MATERIALS, BIOCOMPATIBLE; DRUG LIBERATION; FLUOROURACIL; HUMANS; HYALURONIC ACID; LIPIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOMEDICINE; NANOSTRUCTURES; PRODRUGS; STOMACH NEOPLASMS;

EID: 84933566489     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S83211     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G, Zagonel V. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol. 2012;81(1):38–48.
3. Yang W, Rauf A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 2014;1846(1):232–237.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
5. Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine. 2014;9:5449–5460.
6. Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013;334(2):338–345.
7. Luan J, Zhang D, Hao L, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nano-structured lipid carriers. Colloids Surf B Biointerfaces. 2014;114: 255–260.
8. Mura S, Bui DT, Couvreur P, Nicolas J. Lipid prodrug nanocarriers in cancer therapy. J Control Release. 2015;208:25–41.
9. Negi LM, Talegaonkar S, Jaggi M, et al. Surface engineered nano-structured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids Surf B Biointerfaces. 2014;123:600–609.
10. Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 2011;32(29):71817190.
11. Han HS, Lee J, Kim HR, et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. J Control Release. 2013;168(2): 105–114.
12. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol. 2008;14(41):6376–6381.
13. Wang DR, Chen GY, Liu XL, et al. CD44v6 in peripheralblood and bone marrow of patients with gastric cancer as micro-metastasis. World J Gastroenterol. 2006;12(1):36–42.
14. Aghcheli K, Parsian H, Qujeq D, et al. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. Eur J Intern Med. 2012;23(1):58–64.
15. Ya o HJ, Zhang YG, Sun L, Liu Y. The effect of hyaluronic acid func-tionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014;35(33):9208–9223.
16. Gomez-Martín C, Lopez-Rios F, Aparicio J, et al. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastu-zumab, and beyond. Cancer Lett. 2014;351(1):30–40.
17. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol. 2009;10(11):1063–1069.
18. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687–697.
19. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39(1):60–67.
20. Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12(9):1301–1306.
21. Giorgio E, Caroti C, Mattioli F, et al. Severe fuoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355–1361.
22. Ashwanikumar N, Kumar NA, Nair SA, Kumar GS. 5-Fluorouracil-lipid conjugate: potential candidate for drug delivery through encapsulation in hydrophobic polyester-based nanoparticles. Acta Biomater. 2014;10(11):4685–4694.
23. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7): 939–950.
24. Contino C, Maurizis JC, Pucci B. Synthesis and preliminary biological assessments of a new class of amphiphilic telomers bearing 5-fluorouracil moieties. Macromol Chem Phys. 1999;200(6):1351–1355.
25. Nichifor M, Schacht EH, Seymour L W. Polymeric prodrugs of 5-fluorouracil. J Control Release. 1997;48(2–3):165–178.
26. Cui SX, Zhang HL, Xu WF, Qu XJ. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/ CD13). Eur J Pharmacol. 2014;734:50–59.
27. Thomas AM, Kapanen AI, Hare JI, et al. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release. 2011;150(2):212–219.
28. Ghasemi Z, Dinarvand R, Mottaghitalab F, Esfandyari-Manesh M, Sayari E, Atyabi F. Aptamer decorated hyaluronan/chitosan nanopar-ticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. Carbohydr Polym. 2015;121:190–198.
29. Li Q, Du YZ, Yuan H, et al. Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system. Eur J Pharm Sci. 2010;41(3–4): 498–507.
30. Zhu S, Wonganan P, Lansakara PDS, O’Mary HL, Li Y, Cui Z. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Bioma-terials. 2013;34(9):2327–2339.
31. Yu BT, Sun X, Zhang ZR. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res. 2003;26:1096–1101.
32. Rautio J, Kumpulainen H, Heimbach T. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255–270.
33. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotec-tive strategies. Kidney Int. 2008;73(9):994–1007.
34. Sengupta P, Basu S, Soni S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A. 2012;109(28): 11294–11299.
35. Guo S, Miao L, Wang Y, Huang L. Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release. 2014;174:137–142.
36. Wang Y, Zhou J, Qiu L, et al. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials. 2014;35(14):4297–4309.
37. Liu Z, Rimmer S. Synthesis and release of 5-fluorouracil from poly(N-vinylpyrrolidinone) bearing 5-fluorouracil derivatives. J Control Release. 2002;81(1–2):91–99.
38. Farshori NN, Banday MR, Zahoor Z, Rauf A. DCC/DMAP mediated esterification of hydroxy and non-hydroxy olefnic fatty acids with β-sitosterol: in vitro antimicrobial activity. Chin Chem Lett. 2010;21(6): 646–650.
39. Fan X, Chen J, Shen Q. Docetaxel-nicotinamide complex-loaded nano-structured lipid carriers for transdermal delivery. Int J Pharm. 2013; 458(2):296–304.
40. Luan J, Zhang D, Hao L, et al. Preparation, characterization and phar-macokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;114:255–260.
41. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nano-particle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002;79(1–3):123–135.
42. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681.
43. Yan LH, Wei WY, Cao WL, Zhang XS, Xie YB, Xiao Q. Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance. Am J Cancer Res. 2014;5(1):321–332.
44. Fata F, Ron IG, Kemeny N, O’Reilly E, Klimstra D, Kelsen DP. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999;86:1129–1134.
45. Ashwanikumar N, Kumar NA, Nair SA, Kumar GSV. Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon. Int J Nanomedicine. 2012;7:5769–5779.
46. Liu Z, Rimmer S. Synthesis and release of 5-fluorouracil from poly (N-vinylpyrrolidinone) bearing 5-fluorouracil derivatives. J Control Release. 2002;81:91–99.
47. Platt VM, Szoka FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharmacol. 2008;5(4):474–486.
48. Peer D, Margalit R. Loading mitomycin C inside long circulation hyaluronan targeting nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer. 2004;108:780–789.
49. Mizrahy S, Raz SR, Hasgaard M, et al. Hyaluronan-coated nanopar-ticles: the infuence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release. 2011;156: 231–238.
50. Han Y, Zhang Y, Li D, Chen Y, Sun J, Kong F. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine. 2014;9: 4107–4116.
51. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008;9(2):435–443.
52. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004;10(23):7994–8004.
53. Feng T, Tian H, Xu C, et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm. 2014;88(3):1086–1093.